The lead drug in a wide-ranging Alzheimer’s disease collaboration between Biogen and Eisai has flunked its first test, falling short of its main goal in a mid-stage clinical trial.
Biogen (NASDAQ: BIIB) and Eisai said Thursday an independent interim analysis at 12 months found that the drug BAN2401 failed to show enough of a change on assessment scores used to evaluate patients in the early stages of Alzheimer’s disease. But the companies will continue the study to gather more data.
BAN2401 is a monoclonal antibody that binds to amyloid beta plaque to break up the accumulation of this protein on… Read more »
UNDERWRITERS AND PARTNERS